<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Doxapram: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Doxapram: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Doxapram: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9388" href="/d/html/9388.html" rel="external">see "Doxapram: Drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F162830"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Dopram</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1058200"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Central Nervous System Stimulant</span>;</li>
<li>
<span class="list-set-name">Respiratory Stimulant</span></li></ul></div>
<div class="block don drugH1Div" id="F53462432"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="16eedcbb-51a0-47e2-8621-cf67cc707bf4">Apnea of prematurity, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Apnea of prematurity, refractory:</b> Limited data available: <b>Note: </b>Typically considered third-line agent.</p>
<p style="text-indent:-2em;margin-left:4em;">Preterm neonates:</p>
<p style="text-indent:-2em;margin-left:6em;">Loading dose: IV: 2.5 to 3 mg/kg (Bhatt-Mehta 2003; de Waal 2019; Peliowski 1990; Tay-Uyboco 1991).</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance dose: Continuous IV infusion: Initial: 0.5 to 1.5 mg/kg/hour; increase in increments of 0.5 mg/kg/hour as needed to control apnea up to a maximum rate of 2.5 mg/kg/hour; once stable titrate to the lowest rate at which apnea is controlled; assess benzyl alcohol exposure particularly with higher doses or continued use (Barrington 1987; Bhatt-Mehta 2003; de Waal 2019; Peliowski 1990; Prins 2013; Sreenan 2001; Tay-Uyboco 1991).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F15508759"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Although manufacturer's dosing recommendations are presented for these FDA-approved indications, use of doxapram has largely been replaced by alternate preferred agents.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="67e380e7-3e71-4be4-99d8-257d4f962e22">Drug-induced CNS depression</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Drug-induced CNS depression:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: IV:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Intermittent injection:</i> Initial: Priming dose of 1 to 2 mg/kg; repeat after 5 minutes; may repeat at 1 to 2 hour intervals until sustained consciousness; if relapse occurs may resume repeat doses at 1 to 2 hour intervals until sustained consciousness or maximum dose reached; maximum daily dose: 3,000 mg/<b>day</b>. May repeat in 24 hours if necessary; repeat doses should only be given to patient who demonstrated a response to initial dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>IV infusion:</i> Initial: Priming dose of 1 to 2 mg/kg; repeat after 5 minutes. If no response, wait 1 to 2 hours and repeat priming dose. If some respiratory stimulation is noted, initiate infusion at 1 to 3 mg/minute (depending on size of patient/depth of CNS depression); suspend infusion if patient begins to awaken. Infusion should not be continued for &gt;2 hours. May reinstitute infusion as described above, including bolus, after rest interval of 30 minutes to 2 hours; maximum daily dose: 3,000 mg/<b>day</b>.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9bfed65b-2153-4c33-8371-fc9df958a5b6">Respiratory depression following anesthesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Respiratory depression following anesthesia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: IV:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Intermittent injection:</i> Initial: 0.5 to 1 mg/kg; may repeat at 5-minute intervals; maximum single injection dose: 1.5 mg/kg; maximum total dose: 2 mg/kg.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Continuous IV infusion:</i> Initial: 5 mg/minute until adequate response or adverse effects seen; decrease to 1 to 3 mg/minute; maximum total dose: 4 mg/kg (in an average adult, ~300 mg total dose).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51094201"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling (has not been studied); however, use caution in severe impairment due to the potential for altered pharmacokinetics.</p></div>
<div class="block dohp drugH1Div" id="F51094202"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling (has not been studied); however, use caution in severe impairment due to the potential for altered pharmacokinetics.</p></div>
<div class="block doa drugH1Div" id="F162832"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9388" href="/d/html/9388.html" rel="external">see "Doxapram: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Although manufacturer's dosing recommendations are presented for these FDA-approved indications, use of doxapram has largely been replaced by alternate preferred agents.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9bfed65b-2153-4c33-8371-fc9df958a5b6">Respiratory depression following anesthesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Respiratory depression following anesthesia: IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Intermittent injection:</i> Initial: 0.5 to 1 mg/kg; may repeat at 5-minute intervals (only in patients who demonstrate initial response); maximum single injection dose: 1.5 mg/kg; maximum total dose: 2 mg/kg.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>IV infusion:</i> Initial: 5 mg/minute until adequate response or adverse effects seen; decrease to 1 to 3 mg/minute; maximum total dose: 4 mg/kg.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="67e380e7-3e71-4be4-99d8-257d4f962e22">Drug-induced CNS depression</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Drug-induced CNS depression: IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Intermittent injection:</i> Initial: Priming dose of 1 to 2 mg/kg; repeat after 5 minutes (only in patients who demonstrate initial response); may repeat at 1 to 2 hour intervals (until sustained consciousness); maximum: 3000 mg/day. May repeat in 24 hours if necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>IV infusion:</i> Initial: Priming dose of 1 to 2 mg/kg repeated in 5 minutes. If no response, wait 1 to 2 hours and repeat priming dose. If some stimulation is noted, initiate infusion at 1 to 3 mg/minute (depending on size of patient/depth of CNS depression); suspend infusion if patient begins to awaken. Infusion should not be continued for &gt;2 hours. May reinstitute infusion as described above, including bolus, after rest interval of 30 minutes to 2 hours; maximum: 3000 mg/day.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cecbb986-8276-4951-8184-32f998d7bf67">Acute hypercapnia secondary to COPD</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute hypercapnia secondary to COPD: IV infusion:</b> Initial: Initiate infusion at 1 to 2 mg/minute (depending on size of patient/depth of CNS depression); may increase to maximum rate of 3 mg/minute; infusion should not be continued for &gt;2 hours. Additional infusions are not recommended (per manufacturer).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991697"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, use caution in severe impairment due to the potential for altered pharmacokinetics.</p></div>
<div class="block doha drugH1Div" id="F50989013"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, use caution in severe impairment due to the potential for altered pharmacokinetics.</p></div>
<div class="block adr drugH1Div" id="F162806"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Cardiac arrhythmia, change in pulse, chest pain, chest tightness, flattened T wave on ECG, flushing, increased blood pressure, phlebitis, ventricular fibrillation, ventricular tachycardia</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Apprehension, clonus, disorientation, dizziness, hallucination, headache, hyperactivity, hyperreflexia, involuntary muscle movements, paresthesia, positive Babinski sign, seizure</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Burning sensation of skin, diaphoresis, pruritus</p>
<p style="text-indent:-2em;margin-left:2em;">Endocrine &amp; metabolic: Albuminuria</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Bowel urgency, diarrhea, hiccups, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:2em;">Genitourinary: Urinary incontinence, urinary retention</p>
<p style="text-indent:-2em;margin-left:2em;">Hematologic &amp; oncologic: Decreased hematocrit, decreased hemoglobin, hemolysis, decreased red blood cells</p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular &amp; skeletal: Fasciculations, laryngospasm, muscle spasm</p>
<p style="text-indent:-2em;margin-left:2em;">Ophthalmic: Mydriasis</p>
<p style="text-indent:-2em;margin-left:2em;">Renal: Increased blood urea nitrogen</p>
<p style="text-indent:-2em;margin-left:2em;">Respiratory: Bronchospasm, cough, dyspnea, hyperventilation, hypoventilation (rebound), tachypnea</p>
<p style="text-indent:-2em;margin-left:2em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Agitation (emergence), prolonged QT interval on ECG (premature neonates), second degree atrioventricular block (premature neonates)</p></div>
<div class="block coi drugH1Div" id="F162819"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to doxapram or any component of the formulation; significant cardiovascular impairment (eg, uncompensated heart failure, severe coronary artery disease); severe hypertension (including severe hypertension associated with hyperthyroidism or pheochromocytoma); cerebral edema, cerebral vascular accident, epilepsy or other convulsive disorders, head injury; mechanical disorders of ventilation (eg, mechanical obstruction, muscle paresis, neuromuscular blockade, flail chest, pneumothorax, acute asthma, pulmonary fibrosis), pulmonary embolism (proven or suspected)</p></div>
<div class="block war drugH1Div" id="F162803"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular effects: May cause dysrhythmias; monitor for disturbances of cardiac rhythm. If sudden hypotension develops during use, discontinue. Increases in blood pressure are generally modest; use is contraindicated in patients with severe hypertension.</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS stimulation: May cause severe CNS stimulation, including seizures; antiseizure medications (as well as oxygen and resuscitative equipment) should be available to manage potential excessive CNS stimulation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cerebrovascular disease: Use with caution in patients with cerebrovascular disease; lowered pCO<sub>2</sub> induced by hyperventilation produces cerebral vasoconstriction and decreased circulation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory disease: Do <b>not</b> use in patients on mechanical ventilation. Use with caution in treating pulmonary disease; a pressor effect on pulmonary circulation may result in a fall in arterial pO<sub>2</sub>. If sudden dyspnea develops during use, discontinue. Doxapram causes patients to increase the work of breathing; therefore, do not increase the rate of infusion in an attempt to lower the pCO<sub>2</sub> in severely-ill COPD patients.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• MAO inhibitors (MAOIs): Use caution with coadministration; additive pressor effect may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sympathomimetics: Use caution with coadministration; additive pressor effect may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Volatile anesthetics: If patient has received anesthesia with a volatile agent known to sensitize the myocardium to catecholamines, avoid use of doxapram until anesthetic has been eliminated to decrease the risk of ventricular tachycardia or ventricular fibrillation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP ["Inactive" 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors, 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Administration: Avoid extravasation; doxapram may cause thrombophlebitis or local skin irritation. Hemolysis may result from rapid infusion.</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Adequate airway required prior to use; consider airway protection in case of vomiting. Resuscitative equipment (in addition to antiseizure medications and oxygen) should be readily available; doxapram alone may not be sufficient to stimulate spontaneous breathing or provide sufficient arousal. Doxapram is neither an antagonist to skeletal muscle relaxants nor an opioid antagonist. Use with caution in patients with hypermetabolic states (eg, hyperthyroidism, pheochromocytoma).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878432"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Recommended doses of doxapram for treatment of neonatal apnea will deliver 5.4 to 27 mg/kg/day of benzyl alcohol; the use of doxapram should be reserved for neonates who are unresponsive to the treatment of apnea with therapeutic serum concentrations of theophylline or caffeine; monitor benzyl alcohol exposure, particularly with prolonged therapy or high doses.</p>
<p style="text-indent:0em;margin-top:2em;">Possible adverse effects on mental development (based on developmental scales and index scoring) have been reported in former premature neonates (Lando 2005, Sreenan 2001). A case-controlled trial of 80 children who weighed &lt;1,250 g at birth (mean GA: ~26.5 weeks, corrected age at assessment: 18 months) reported a significant correlation between isolated adverse mental development and total cumulative dose of doxapram (mean: 2,233 mg [cases] vs 615 mg [controls]) and duration of therapy (mean: 45.2 days [cases] vs 19.4 days [controls]) (Sreenan 2001). Another report of 88 former premature neonates (GA &lt;28 weeks) showed an association between doxapram therapy and lower developmental scores later in infancy and early childhood (age at assessment was 9 to 15 months corrected age) (Lando 2005).</p>
<p style="text-indent:0em;margin-top:2em;">Use with caution in premature neonates and infants; hypertension (dose related), irritability, jitteriness, erratic limb movements, excessive crying, sleep disturbances, abdominal distention, vomiting, necrotizing enterocolitis, increased gastric residuals, bloody stools, hyperglycemia, glycosuria, premature eruption of teeth, and QT prolongation resulting in heart block have been reported. Seizures have been reported in premature neonates who have additional seizure risk factors including a history of seizures, perinatal asphyxia, intracerebral hemorrhage or recent aminophylline, theophylline, or caffeine exposure.</p></div>
<div class="block foc drugH1Div" id="F162814"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dopram: 20 mg/mL (20 mL) [contains benzyl alcohol]</p></div>
<div class="block geq drugH1Div" id="F162799"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16323120"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Dopram Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/mL (per mL): $3.19</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F52612624"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: IV: Administer as an intermittent bolus or as an IV infusion. Loading doses for apnea of prematurity have been infused over 15 minutes (de Waal 2019). Avoid rapid infusion. Avoid extravasation; irritating to tissues.</p></div>
<div class="block adm drugH1Div" id="F162816"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: Administer IV as an intermittent bolus or as an IV infusion. Avoid rapid infusion. Avoid extravasation.</p></div>
<div class="block sts drugH1Div" id="F162827"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store intact vials at 20°C to 25°C (68°F to 77°F).</p></div>
<div class="block usep drugH1Div" id="F53566578"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Respiratory stimulant for respiratory depression secondary to anesthesia, mild to moderate drug-induced respiratory and CNS depression, and acute hypercapnia secondary to chronic obstructive pulmonary disease (COPD) (FDA approved in ages ≥12 years and adults); has also been used to treat apnea of prematurity refractory to methylxanthine therapy.</p></div>
<div class="block mst drugH1Div" id="F162864"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Doxapram may be confused with doxazosin, doxepin, DOXOrubicin </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dopram® may be confused with DOPamine</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Doxapram may be confused with Doxinate brand name for doxylamine and pyridoxine [Italy]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299230"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F162808"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Atomoxetine: May enhance the hypertensive effect of Sympathomimetics. Atomoxetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the adverse/toxic effect of Sympathomimetics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levothyroxine: May enhance the adverse/toxic effect of Sympathomimetics. Specifically, the risk of coronary insufficiency may be increased in patients with coronary artery disease. Levothyroxine may enhance the therapeutic effect of Sympathomimetics. Sympathomimetics may enhance the therapeutic effect of Levothyroxine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Consider initial dose reductions of sympathomimetic agents, and closely monitor for enhanced blood pressure elevations, in patients receiving linezolid.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Doxapram.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Sympathomimetics may enhance the tachycardic effect of Solriamfetol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F162821"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events have not been observed in animal reproduction studies.</p></div>
<div class="block mopp drugH1Div" id="F53566577"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Pulse oximetry, blood pressure, heart rate, ECG, arterial blood gases, deep tendon reflexes.</p></div>
<div class="block rerp drugH1Div" id="F53566133"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Apnea of prematurity: Data suggest a therapeutic serum concentration of at least 1.5 mg/L; toxicity becomes frequent at serum concentrations &gt;4 to 5 mg/L (Barbé 1999; Barrington 1987).</p></div>
<div class="block pha drugH1Div" id="F162802"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Stimulates respiration through action on peripheral carotid chemoreceptors; respiratory center in medulla is also directly stimulated as dosage is increased</p></div>
<div class="block phk drugH1Div" id="F162818"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Respiratory stimulation: Single IV injection: 20 to 40 seconds.</p>
<p style="text-indent:-2em;margin-left:4em;">Peak effect: Single IV injection: 1 to 2 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Single IV injection: 5 to 12 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: Neonates (GA: 24 to 32 weeks; PNA: 6 to 60 days): 7.33 ± 4.55 L/kg (Jamali 1988).</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensive in the liver to active metabolite (keto-doxapram).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination, serum:</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates (GA: 24 to 32 weeks; PNA: 6 to 60 days): 8.17 ± 4.13 hours (Jamali 1988).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Mean: 3.4 hours (range: 2.4 to 4.1 hours) (Robson 1979).</p>
<p style="text-indent:-2em;margin-left:2em;">Clearance: Neonates (GA: 24 to 32 weeks; PNA: 6 to 60 days): 0.7 ± 0.49 L/hour/kg (Jamali 1998).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038604"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Dopram</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Dopram</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Dopram</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Dopram</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Doxapram</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Dopram</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Dopram</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Docatone</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Dopram</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Dopram</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Dopram | Doxapram</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Dopram | Doxapram</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Caropram</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Dopram</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Dopram | Mopram | Tapram</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Dopram</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Dopram</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Dopram</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Dopram</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Dopram</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Dopram</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Dopram</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Dopram</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Dopram</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Dopram | Doprem</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxapram-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10519454">
<a name="10519454"></a>Barbé F, Hansen C, Badonnel Y, Legagneur H, Vert P, Boutroy MJ. Severe side effects and drug plasma concentrations in preterm infants treated with doxapram. <i>Ther Drug Monit</i>. 1999;21(5):547-552.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxapram-pediatric-drug-information/abstract-text/10519454/pubmed" id="10519454" target="_blank">10519454</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3110729">
<a name="3110729"></a>Barrington KJ, Finer NN, Torok-Both G, et al, “Dose-Response Relationship of Doxapram in the Therapy for Refractory Idiopathic Apnea of Prematurity,” <i>Pediatrics</i>, 1987, 80(1):22-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxapram-pediatric-drug-information/abstract-text/3110729/pubmed" id="3110729" target="_blank">3110729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12608884">
<a name="12608884"></a>Bhatt-Mehta V and Schumacher RE, “Treatment of Apnea of Prematurity,” <i>Paediatr Drugs</i>, 2003, 5(3):195-210.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxapram-pediatric-drug-information/abstract-text/12608884/pubmed" id="12608884" target="_blank">12608884</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcoho - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxapram-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9672531">
<a name="9672531"></a>De Villiers GS, Walele A, Van der Merwe PL, et al, “Second-Degree Atrioventricular Heart Block After Doxapram Administration,” <i>J Pediatr</i>, 1998, 133(1):149-50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxapram-pediatric-drug-information/abstract-text/9672531/pubmed" id="9672531" target="_blank">9672531</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30352445">
<a name="30352445"></a>de Waal CG, Hutten GJ, Kraaijenga JV, de Jongh FH, van Kaam AH. Doxapram treatment and diaphragmatic activity in preterm infants. <i>Neonatology</i>. 2019;115(1):85-88. doi:10.1159/000493359<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxapram-pediatric-drug-information/abstract-text/30352445/pubmed" id="30352445" target="_blank">30352445</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Dopram (doxapram hydrochloride) [prescribing information]. Berkeley Heights, NJ: Hikma Pharmaceuticals USA Inc; June 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16303710">
<a name="16303710"></a>Lando A, Klamer A, Jonsbo F, Weiss J, Greisen G. Doxapram and developmental delay at 12 months in children born extremely preterm. <i>Acta Paediatr</i>. 2005;94(11):1680-1681.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxapram-pediatric-drug-information/abstract-text/16303710/pubmed" id="16303710" target="_blank">16303710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxapram-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3191816">
<a name="3191816"></a>Jamali F, Barrington KJ, Finer NN, Coutts RT, Torok-Both GA. Doxapram dosage regimen in apnea of prematurity based on pharmacokinetic data. <i>Dev Pharmacol Ther</i>. 1988;11(5):253-257. doi:10.1159/000457699<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxapram-pediatric-drug-information/abstract-text/3191816/pubmed" id="3191816" target="_blank">3191816</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11753270">
<a name="11753270"></a>Maillard C, Boutroy MJ, Fresson J, et al, “QT Interval Lengthening in Premature Infants Treated With Doxapram,” <i>Clin Pharmacol Ther</i>, 2001, 70(6):540-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxapram-pediatric-drug-information/abstract-text/11753270/pubmed" id="11753270" target="_blank">11753270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2181103">
<a name="2181103"></a>Peliowski A, Finer NN. A blinded, randomized, placebo-controlled trial to compare theophylline and doxapram for the treatment of apnea of prematurity. <i>J Pediatr</i>. 1990;116(4):648-653.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxapram-pediatric-drug-information/abstract-text/2181103/pubmed" id="2181103" target="_blank">2181103</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24376463">
<a name="24376463"></a>Prins SA, Pans SJ, van Weissenbruch MM, Walther FJ, Simons SH. Doxapram use for apnoea of prematurity in neonatal intensive care. <i>Int J Pediatr</i>. 2013;2013:251047. doi:10.1155/2013/251047<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxapram-pediatric-drug-information/abstract-text/24376463/pubmed" id="24376463" target="_blank">24376463</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32901">
<a name="32901"></a>Robson RH and Prescott LF, “A Pharmacokinetic Study of Doxapram in Patients and Volunteers,” <i>Br J Clin Pharmacol</i>, 1979, 7(1):81-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxapram-pediatric-drug-information/abstract-text/32901/pubmed" id="32901" target="_blank">32901</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11743509">
<a name="11743509"></a>Sreenan C, Etches PC, Demianczuk N, Robertson CM. Isolated mental developmental delay in very low birth weight infants: association with prolonged doxapram therapy for apnea. <i>J Pediatr</i>. 2001;139(6):832-837.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxapram-pediatric-drug-information/abstract-text/11743509/pubmed" id="11743509" target="_blank">11743509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2070020">
<a name="2070020"></a>Tay-Uyboco J, Kwiatkowski K, Cates DB, Seifert B, Hasan SU, Rigatto H. Clinical and physiological responses to prolonged nasogastric administration of doxapram forapnea of prematurity. <i>Biol Neonate</i>. 1991;59(4):190-200.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxapram-pediatric-drug-information/abstract-text/2070020/pubmed" id="2070020" target="_blank">2070020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20526708">
<a name="20526708"></a>Yu D, Chai W, Sun X, et al, “Emergence Agitation in Adults: Risk Factors in 2,000 Patients,” <i>Can J Anaesth</i>, 2010, 57(9):843-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxapram-pediatric-drug-information/abstract-text/20526708/pubmed" id="20526708" target="_blank">20526708</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13252 Version 157.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
